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CObjectives: Estimates regarding the impact of secondary cardiovascu-
lar events on health status in patients treated for cardiovascular dis-
ease are scarce and of limited accuracy. Methods: We obtained indi-
vidual patient data on health status (EuroQol five-dimensional
questionnaire) and secondary cardiovascular events (death, myocar-
dial infarction, cerebrovascular accidents, amputation, extracranial
bleeding, and reinterventions) observed during 12 to 36 months of fol-
low-up. Data originated from five completed clinical trials on revascu-
larization in coronary heart disease (n  2593) or peripheral arterial
disease (PAD; n  1379). We used linear mixed-effects modeling to
estimate the acute impact of the initial secondary event and the health
status before and after the event. Results: A total of 1595 patients had
at least one secondary event. Loss of health status just before the event
ranged from 0.36 utility score for amputation in women with PAD to
zero for cerebrovascular accident in men with PAD. In patients with
coronary heart disease, pre-event health status loss ranged from 0.34 O
o rep
ealt
00, 3
al So
doi:10.1016/j.jval.2011.09.004or extracranial bleeding in women to 0.10 for myocardial infarction in
omen. The acute impact of secondary events ranged from minor de-
erioration for cerebrovascular accident (0.03) to improvement after
ll other events, ranging from 0.01 for occlusion to 0.22 for ampu-
ation. Women had significantly lower pre-event scores than did men:
0.04 to 0.10 in coronary heart disease and 0.04 to 0.27 in PAD.
lder patients had mostly large but insignificantly lower pre-event
cores than did younger patients (range 0.04 to 0.67).
onclusions: Secondary events after revascularization in patients
ith cardiovascular disease are associated with health status loss be-
ore the event, while acute impact of the events was mostly small.
eywords: cardiovascular events, coronary heart diseases, health
tatus, individual patient data, peripheral vascular disease, outcome
ssessment (health care), technology assessment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Patients with advanced cardiovascular disease are often treated
with invasive interventions, such as angioplasty or bypass graft-
ing. The short-term efficacy and cost-effectiveness of these inter-
ventions is well documented [1–8].
Economic evaluation based on actual long-term individual pa-
tient data, however, is both difficult and costly. Generally, esti-
mates of long-term cost-effectiveness are obtained by using a
modeling approach where various sources of evidence are inte-
grated. A widely used outcome measure in cost-effectiveness
studies is a combination of quantity and quality of life: the well-
known quality-adjusted life-year (QALY). One of the challenges in
long-term economic modeling is the uncertainty surrounding the
estimates that are used in the model. Sources and methods of
obtaining the estimates for the input parameters vary. This vari-
ability may be associated with lack of accuracy in the estimates,
for example, when relatively few events are observed. Clearly, all
variability in themodel parameterswill ultimately add to the over-
all uncertainty regarding the long-term cost-effectiveness [9].
Among the major drivers of long-term cost-effectiveness is the
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Published by Elsevier Inc.impact of subsequent adverse health outcomes. Both frequency
and (dis)utility will ultimately determine the overall outcome. In
cardiovascular disorders, rather accurate and validated estimates
of the frequency of subsequent events may be obtained through
regression-based prognostic models, for example, based on the
Framingham study [10]. Also, clinical studies actually recording
clinical outcome have been reported [11,12]. In the absence of ac-
curate data on the effect of secondary cardiovascular events, that
is, subsequent events that occur after the intervention, consider-
able uncertainty in modeling long-term outcome will remain. We
found only some estimates for cerebrovascular accidents (CVAs)
[13–16], which differed in assessment method and values.
Amajor reason for this lack of accuracy is that individual studies
may be powered on expected differences in event rates but still will
rarely observe sufficient numbers of specific secondary cardiovascu-
lar events to obtain accurate estimates of their individual impacts.
Typically, around 10% to 40% of secondary cardiovascular events are
anticipated within 1 year in the patients enrolled in a randomized
controlled trial on cardiovascular revascularization [17]. These sec-
ondaryeventscompriseseveral typesofevents, suchasdeath,myocar-
dial infarction (MI), and reinterventions. Thus, only small numbers of
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tainty (wide confidence intervals) regarding the estimates of the im-
pact of new events on health status from a single trial.
To overcome this barrier and accurately estimate the impact of
secondary cardiovascular events, we set out to pool individual pa-
tient data from completed clinical trials on interventions aimed at
revascularization in patients with cardiovascular diseases (see trial
descriptions in Table 1). The trials were selected to include patients
ith coronaryheart disease (CHD) or peripheral artery disease (PAD).
We report here both the acute impact of having a secondary
event and the overall impact, that is, the loss of health status
compared with patients without an event.
Methods
Individual patient data on health status, secondary cardiovascular
events, andpatient characteristicswere obtained fromfive trials (see
Table 1 for full names and descriptions of trials). Three trials re-
cruited patients with CHD: Benestent II [1], ARTS [2], and Octopus
[6–8,17]. Two trials included patients with PAD: BOA [5,18,19] and
DIST [3,4,20]. All cardiovascular events after the vascular interven-
tionunder studyare regardedas secondaryevents.Wedistinguished
Table 1 – Trial description.
Study acronym Stu
ARTS Arterial Revascularization Therapies Study: R
(CABG) vs. percutaneous transluminal coro
patients requiring coronary revascularizat
BENESTENT Randomized comparison of PTCA with and w
coronary
BOA Bypass, Oral anticoagulents or Aspirin study:
aspirin for the prevention of occlusions of
from the start of the trial in 593 patients an
cardiovascular event (n  515). This caused
DIST Dutch Iliac Stent Trial: Randomized compari
followed by selective stent placement in p
caused by stenosis or occlusion in the iliac
OctoPump Randomized comparison of on-pump CABG v
coronary revascularization, only eligible fo
OctoStent Randomized comparison of PTCA with stent
patients requiring coronary revascularizat
* See Table 2 for study characteristics.
† Off-pump CABG uses the Octopus Tissue Stabilizer, which allows r
bypass.
Table 2 – Trial characteristics.
Trial name Trial arm Patient type N pa
ARTS CABG CHD 6
PTCA  stent 6
BENESTENT PTCA CHD 4
PTCA  stent 4
BOA Aspirin PAD 5
OAC 5
DIST PTA  primary stent PAD 1
PTA  selective stent 1
OctoPump On-pump CABG CHD 1
Off-pump CABG 1
OctoStent PTCA CHD 1
Off-pump CABG 1
For abbreviations and acronyms of trial names, see Table 1. CABG,
anticoagulant; PAD, peripheral artery disease; PTCA, percutaneous transluthe initial secondary event and subsequent events. As there were
insufficient further events to fit statistical models, we chose to con-
fine the analyses to the first event after the vascular intervention.
Health status was measured with the EuroQol five-dimensional
(EQ-5D) questionnaire [21], oncebefore thevascular interventionand
several times after the intervention. The EQ-5D health status instru-
ment comprises five questions—each with three levels—represent-
ing five health domains: pain, mood, mobility, self-care, and daily
activities. This results in 243 health states. The EQ-5D utility score
was computed by using the MVH-A1 algorithm [22]. This algorithm
yields a score ranging from 0.594 to 1.00 (full health). A value of
zero represents death; negative values imply a health state worse
than death. An interaction term adjusts for an extra decrease in util-
ity when one of the dimensions is at the most severe level.
Secondary cardiovascular events included death, MI, CVA, am-
putation, infrainguinal-vein-graft occlusion, extracranial bleed-
ing, and reinterventions. The latter comprised percutaneous
transluminal coronary angioplasty, percutaneous transluminal
angioplasty, and coronary artery bypass grafting.
The number of measurements and the length of follow-up
were different for the included trials (Table 2). The length of fol-
low-up was between 12 and 36 months.
escription Reference
mized comparison of coronary artery bypass grafting
angioplasty (PTCA) with stenting in cardiovascular
2
t stenting in cardiovascular patients requiring 1
omized comparison of oral anticoagulant therapy vs.
nguinal bypasses. Health status data were collected
the rest of the patients only after a secondary
sing data in the period before the event
5, 18, 19
f primary stent placement vs. primary angioplasty
s with intermittent claudication or critical ischemia
ies
3, 4, 20
-pump CABG* in cardiovascular patients requiring
G
6, 8, 17
ntation vs. off-pump† CABG in cardiovascular
ligible for PTCA with stent implantation
7, 17
cularization on the beating heart without needing cardiopulmonary
ts Age Gender (% male) Follow-up months
61.2 (9.3) 76.0 1, 6, 12, 36
60.7 (9.6) 77.0
58.4 (10.5) 77.3 1⁄2, 1, 6, 12
58.1 (10.5) 80.0
67.9 (10.0) 63.7 3, 9, 15, 21, 27, 33
68.4 (9.9) 64.0
57.9 (10.2) 72.7 3, 12, 24
57.9 (10.6) 71.3
61.2 (9.1) 70.2 1, 3, 12
60.3 (8.9) 66.2
60.3 (9.1) 70.3 1, 6, 12
58.8 (9.9) 71.8
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The magnitude of the impact of secondary events was estimated
by first modeling the course of health status separately for pa-
tients with and without an event. For patients without an event,
the course of health statuswasmodeled by using postintervention
data only, using linear mixed-effects modeling. For patients with
an event, we assumed that the event might relate to an already
reduced health state before the event. For this reason, the course
before and after eventswasmodeled by using linearmixed-effects
modeling [23], after rearranging all events and measurements on
the timeline. Initial secondary events were placed at t 0 for each
patient. The time points of measurement were recalculated as
days before or after the secondary event. An indicator variablewas
used for labeling whether a health status measurement was be-
fore or after the first (secondary) event. Then, linear mixed-effects
modeling was used to compute the predicted values for the EQ-5D
immediately before and after each type of event [23]. In R, this
reads as follows: model lme(mvhtime  indicator  age  gen-
der). The indicator reflects whether ameasure is before or after the
event; mvh is the EQ-5D score. The slopes of the regression model
before and after the event correspond with the rates of deteriora-
tion or improvement. The acute estimated impact of an event can
be derived from the difference between predicted scores immedi-
ately before and after the incident. These analyses were done for
each event separately and for all events together. Age and gender
were included as categorized variables. Age was categorized into
decades from50 to70 (CHD) and60 to80 (PAD). Normality of
the residuals was inspected by a Q-Q plot.
The overall impact of an event on utility was estimated
through comparison of the estimated pre- and postevent utility
scores for patients with a particular event with the 3-month
postintervention scores of patients without any event. We chose
this utility score because the health status of patients without an
event remained the same from that measurement on. The regres-
sion models for patients with an event were used to estimate util-
ity scores at 3 and 6 months pre- and postevent. For patients who
died, the loss in health status in the period before death was esti-
mated by using only the measurements before death. There was
no value imputed for death. The pre- and postevent models and
the nonevent model were then combined in a graphical represen-
tation of the health status pattern and the QALY loss. In these
graphs, only the relevant part of the scoring range is shown to
improve readability.
Possible heterogeneity caused by the use of different patient
groups was analyzed by including an extra level in the linear
mixed-effects model, creating a multilevel model. The treatment
arms in the clinical trials were used as the highest level. This gives
the highest possible amount of units at the levels of treatment
type and patient type [24,25]. Both multilevel and “single”-level
(i.e., neglecting the higher-level grouping) analyses were done for
all trials pooled together and separately for the CHD and PAD
groups. Multi- and single-level models (i.e., with and without ad-
justing for trial and intervention group) were compared by using
an analysis of variance to test whether including the extra level
improved the model [23].
Whether missing EQ-5D scores before and after the first event
were nonrandom, that is, related to disease severity, was tested by
using the number of days in hospital during the follow-up period
as a proxy for severity. In the BOA trial, parts of themissing scores
were by design, as almost 600 patients were followed up continu-
ously, and all other patients were measured only after an event
had happened. Difference in hospital days between patients with
or without EQ-5D score pre- or postevent was tested with the
Mann-Whitney U test to allow for the highly skewed distribution.
Statistical analysis was done with SPSS version 12 (SPSS, Inc.,
Chicago, IL), S-plus for Windows version 6.2 (Insightful Corpora-T D M C E In A V F E
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178 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 7 5 – 1 8 2tion, Seattle,WA), and R version 2.12.1 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
This study included 3972 patients from five clinical trials (PAD
1379 patients, CHD 2593 patients), comprising 1595 secondary
events (see Table 3). Secondary events included 91 deaths, 126MIs,
77 CVAs, 111 extracranial bleedings, 298 occlusions, 38 amputa-
tions, and 854 vascular reinterventions (percutaneous translumi-
nal angioplasty, percutaneous transluminal coronary angioplasty,
and coronary artery bypass grafting). A total of 48.3% of the EQ-5D
scores before the event and 33.4% of the scores after the event
were missing. Table 4 shows the number of valid measurements
er event type.
Impact
Linear mixed-effects modeling showed that including an extra
level (trial arm) did not influence the results. All analysis of vari-
ances comparing single- and multilevel models were nonsignifi-
cant (all P  0.5). Furthermore, there were no differences between
models with or without random slopes. Therefore, we report only
a single-level random-interceptsmodel for each disease type, cor-
rected for gender, age category, and type of event (Tables 5 and 6;
see detailed versions in Supplemental Materials at doi:10.1016/
j.jval.2011.09.004). Models for each event separately gave the same
results as did a model with all events simultaneously. The tables
show the health status immediately before the event (intercept
estimates) for males in the lowest age group, the deviation from
the intercept for females and older-age categories, the change in
health status due to the event (acute impact), regression coeffi-
cients, that is, decline or improvement per month in the period
before the event and after the event (reported only in the Online
Supplemental Material), and lastly the number of patients and
observations included in the analysis. Interaction terms between
events, time, age, and gender are not reported as these were all
nonsignificant. The model for all patients was clearly a compro-
mise between the PADandCHDmodels, with the result depending
on the number of patients fromeach patient group. Therefore, this
model is not reported. Q-Q plots of the residuals of the models
indicated skew, probably caused by the relatively large number of
EQ-5D scores of 1. Log-transforming the data did not help.
Patients with a secondary event had a lower health status than
did patients without an event. This decrease in health status was
found in all types of events and both before and after the event
(Tables 7 and 8; Figs. 1 to 4). Figures 1 to 4 show only one line per
vent type, using the mean age of the group. Also, in these figures
nly a selected range of theY-axis is shown to improve readability.
omen had significantly and/or relevantly (P  0.03) lower pre-
nd postevent scores thandidmen for all events. Older-age groups
ad sometimes higher but mostly markedly lower pre-event
Table 4 – Number of valid measurements per event type.
Event type Number of valid
0 1 2 3
No event 61 66 109 31
Death 3 21 16 2
Myocardial infarction 6 6 6 1
Cerebrovascular accident 3 5 4
Extracranial bleeding 3 4 8 1
Occlusion 0 6 15 1
Amputation 1 1 5
Reintervention 25 33 58 8cores than did the youngest age group (reference category). Evenlarge deviations from the intercept (up to0.67 in CVA), however,
were not significant. The overall impact of the secondary events is
reported as the loss of health status pre- or postevent compared
with having no event (Tables 7 and 8). Figures 1 to 4 show that both
n CHD and in PAD, the largest part of the impact of any secondary
vent lies in the lower health status before the event. In CHD, the
mpact was largest for bleeding in women. In PAD, the impact was
argest for amputation (both men and women).
The acute impact of the events was mainly positive or margin-
lly negative. Amputation gave a large improvement of 0.22 (P 
.007) in utility. CVA was the only event with a consistently nega-
ive impact, but this impact was very small in both groups and
onsignificant. Utility scores of other events in the PAD group did
ot change appreciably. In the CHD group, MI, extracranial bleed-
ng, and reintervention were associated with a small but statisti-
ally significant improvement of 0.09, 0.16, and 0.07, respectively,
n utility score. Most events showed slow deterioration in the pe-
iod before the event and slow improvement after the event. These
egression coefficients, however, were mostly nonsignificant. The
onsignificance of several estimates (regression coefficients, gen-
er, older age) seems to be related to group size: in PAD, the clin-
cally relevant difference in utility associated with female gender
of 0.08 for CVA and 0.13 for MI) is nonsignificant, while the
bove-mentioned differences for MI and reintervention in CHD
ere similar and significant. None of the large differences for
lder-age groups (up to 0.67) were significant. The regression
oefficients of0.003 in PAD for reintervention are significant, but
imilar coefficients for the less frequent amputation and CVA in
he same group are nonsignificant.
Dropout
We found no evidence for selective dropout of more severe pa-
tients. Patients with an event did not have fewer health status
measurements (mean 3.8) than did patients without an event (3.3–
3.6, all nonsignificant) except for patients who died (mean 2.4, P
0.001, compared with no event). Patients with an occlusion had
significantly more measurements (mean 4.3, P  0.001, compared
with no event). This analysis excluded the patients from the BOA
trial who were included from the moment they had an event, as
these patients did not have pre-event scores by design. Table 4
does not suggest that the dropout pattern differs between event
types. There was also no difference in days in hospital (a proxy for
severity) after the primary intervention between patients with or
without ameasurement after the event (18.4 vs. 18.1 days, P 0.9).
Discussion
This study assessed the impact of secondary cardiovascular
events on health status. Secondary events did have a large overall
impact on health status: not only after the event but also before
the event. Patients with any type of event had decreased health
urements per patient Total number of
measurements
4 5 6 7
1465 301 63 0 8966
18 8 0 0 225
80 16 1 0 454
31 5 0 0 186
23 12 5 0 232
20 50 24 1 567
2 4 1 0 48
290 86 35 1 2216meas
3
0
0
8
0
9
1status both before and after the event when compared with pa-
Table 5 – Pre- and postevent EQ-5D scores for patients with PAD, single-level random effects model.
Intercept 95% CI 60–70* 95% CI 70–80* 95% CI 80* 95% CI Gender:
woman
95% CI Impact of
event
95% CI Npat Nobs
Amputation 0.61 0.28 to 0.94 0.02 0.45 to 0.49 0.26 0.61 to 0.08 0.26 0.62 to 0.10 0.27 0.53 to 0.01 0.22 0.07 to 0.37 28 80
Extracranial bleeding 0.74 0.57 to 0.91 0.01 0.17 to 0.18 0.04 0.13 to 0.21 0.08 0.30 to 0.14 0.22 0.32 to 0.12 0.03 0.06 to 0.11 72 236
Cerebrovascular accident 0.79 0.17 to 1.42 0.09 0.71 to 0.53 0.18 0.81 to 0.36 0.67 1.36 to 0.03 0.08 0.34 to 0.19 0.02 0.15 to 0.20 28 76
Myocardial infarction 0.63 0.42 to 0.84 0.12 0.15 to 0.39 0.10 0.16 to 0.36 — — 0.13 0.40 to 0.14 0.01 0.20 to 0.19 16 72
Occlusion 0.55 0.48 to 0.62 0.04 0.04 to 0.12 0.01 0.08 to 0.08 0.06 0.18 to 0.06 0.04 0.10 to 0.03 0.01 0.03 to 0.06 263 884
Reintervention 0.64 0.59 to 0.69 0.01 0.04 to 0.07 0.02 0.08 to 0.04 0.15 0.27 to 0.4 0.06 0.10 to 0.01 0.01 0.02 to 0.05 460 1534
Death 0.66 0.51 to 0.80 0.12 0.32 to 0.08 41 64
PAD, peripheral artery disease, intercept  estimated EQ-5D score immediately before the event for males, age  60 y; Gender: woman  deviation from intercept for women; impact of event 
deviation from intercept immediately after the event; Npat, number of patients in analysis; Nobs  number of observations, i.e., health status measurements in analysis.
EQ-5D, EuroQol five-dimensional questionnaire.
* Deviation from intercept for age groups.
Table 6 – Pre- and postevent EQ-5D scores for patients with CHD, single-level random effects model.
Intercept 95% CI 50–60* 95% CI 60–70* 95% CI 70* 95% CI Gender:
woman
95% CI Impact of
event
95% CI Npat Nobs
Extracranial bleeding 0.54 0.31 to 0.78 0.07 0.24 to 0.38 0.09 0.19 to 0.37 0.12 0.18 to 0.42 0.06 0.33 to 0.21 0.16 0.01 to 0.31 24 81
Cerebrovascular accident 0.73 0.31 to 1.16 0.19 0.64 to 0.26 0.12 0.32 to 0.56 0.04 0.41 to 0.49 0.10 0.27 to 0.06 0.03 0.13 to 0.07 40 167
Myocardial infarction 0.77 0.67 to 0.87 0.10 0.21 to 0.01 0.10 0.20 to 0.01 0.13 0.25 to 0.01 0.04 0.12 to 0.03 0.09 0.03 to 0.16 101 403
Reintervention 0.73 0.69 to 0.78 0.001 0.05 to 0.05 0.02 0.03 to 0.07 0.04 0.03 to 0.01 0.09 0.14 to 0.05 0.07 0.03 to 0.11 329 1298
Death 0.75 0.57 to 0.93 0.15 0.43 to 0.13 23 43
CHD  coronary heart disease; intercept  estimated EQ-5D-score immediately before the event for males, age  50 y; Gender: woman  deviation from intercept for women; impact of event 
deviation from intercept immediately after the event; Npat  number of patients in analysis; Nobs  number of observations, i.e., health status measurements in analysis (see detailed table in
Supplemental Materials at doi:10.1016/j.jval.2011.09.004).
EQ-5D, EuroQol five-dimensional questionnaire.
* Deviation from intercept for age groups.
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180 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 7 5 – 1 8 2tients without events. Women had a much lower health status
than did men, especially in PAD. We found a low acute impact for
most events, which was unexpected, especially for CVA. This lack
of acute impact is partly explained by the already surprisingly low
health status before the secondary event. Still, no change or even
minor improvement after a cardiovascular event is inconsistent
with our clinical judgment. An explanationmay be that because of
the fixed scheme of health status measurements, the effect of
reinterventions immediately after an event could not be separated
from the impact of the event itself. This implies that a major part
of the impact of secondary cardiovascular events is missed with
the typically used fixed measurement scheme in clinical trials,
which should be taken into account in performing cost-effective-
ness analyses. Of note, amputation was an interesting exception:
the very lowpre-event scoreswere followed by amarked improve-
ment after amputation. This probably indicates the relief from a
very painful situation, namely, gangrene, which is typically the
indication for an amputation.
There were several important differences between the models
for PAD and CHD. Patients with PAD had significantly lower pre-
event scores than did patients with CHD for CVA and vascular
reintervention, and higher pre-event scores for bleeding. Further-
more, only in PAD women had much lower pre-event scores than
didmen for several events: amputation, extracranial bleeding, and
CVA. Themodel including both diseaseswas clearly a compromise
between the two and therefore disregarded. Including an extra
level in the models to allow for possible heterogeneity caused by
pooling different trials did not change the estimates nor did esti-
mating each event separately.
Almost half of the EQ-5D scores before and one-third of scores
after eventsweremissing. Only in the BOA study thiswas partly by
design. Still, even in the group that was measured only after an
Table 7 – Health status loss for pre- or postevent compared
Event Men
Pre-event 95% CI Postevent
Death 0.131 0.048 to 0.311
Extracranial bleeding 0.114 0.124 to 0.353 0.179 
Cerebrovascular accident 0.147 0.282 to 0.577 0.180
Myocardial infarction 0.114 0.012 to 0.217 0.020 
Reintervention 0.147 0.101 to 0.194 0.077
Health status loss is computed as the difference between the estimate
the estimated EQ-5D scores immediately pre- and postevent, respect
mo in that situation.
EQ-5D, EuroQol five-dimensional questionnaire; QALY, quality-adjus
Table 8 – Health status loss for pre- or postevent compared
Event Men
Pre-event 95% CI Postevent
Death 0.114 0.043 to 0.271
Amputation 0.161 0.172 to 0.493 0.057
Extracranial bleeding 0.030 0.147 to 0.208 0.004
Cerebrovascular accident 0.022 0.649 to 0.605 0.044
Myocardial infarction 0.143 0.074 to 0.361 0.148
Occlusion 0.221 0.127–0.315 0.207
Reintervention 0.133 0.057–0.209 0.121
Health status loss is computed as the difference between the estimate
the estimated EQ-5D scores immediately pre- and postevent, respect
mo in that situation.
EQ-5D, EuroQol five-dimensional questionnaire; QALY, quality-adjusted lievent had happened, postevent scores were missing. The number
of missing EQ-5D scores corroborates our impression that mea-
surement of health status often has lower priority in clinical trials.
This is an important threat to the validity of cost-effectiveness
analyses, as selective dropout cannot be excluded, which compli-
cates the imputation of missing data.
We tested for selective dropout of more severe patients. One
may speculate that especially patients with a severe event are not
able to complete a questionnaire. We found, however, no differ-
ence in days in hospital (a proxy for severity) after the primary
intervention between patients with or without a measurement
after the event, and patients with an event had as much health
status measurements as patients without an event. This would
appear to confirm that selective dropout is unlikely.
One of the assumptions of linear mixed-effects modeling is a
normal distribution of the models. None of the models met this
assumption, which is probably caused by the large number of
EQ-5D scores with a (maximum) value of 1. Transforming the data
did not improve the residuals.
When selecting trials to include in this study, we considered to
also use trials on other cardiovascular diseases, such as renal ar-
tery stenosis and aneurysms of the abdominal aorta. We could,
however, obtain only one trial for each of these diseases.We chose
not to use these trials for two reasons. First, the small number of
events in these rather small trials prohibited the linear mixed-
effects model to converge in the separate trials. Second, the find-
ing that the model containing all CHD and PAD trials was a com-
promise between the separate models was a clear sign that data
from different disease types should not be analyzed together.
Changes in health status can also be explained by changes in
comorbidity. In these trials, change in comorbidity, however, was
h no event in patients with CHD.
Women
5% CI Pre-event 95% CI Postevent 95% CI
0.229 0.104 to 0.562
3 to 0.462 0.340 0.020 to 0.700 0.184 0.207 to 0.574
1 to 0.621 0.199 0.260 to 0.659 0.232 0.238 to 0.701
0 to 0.141 0.104 0.022 to 0.231 0.010 0.132 to 0.152
7 to 0.137 0.188 0.122 to 0.354 0.117 0.042 to 0.193
-5D score for patients without an event at 3-mo postintervention and
This difference can be divided by 12 to get the QALY loss for being 1
fe-year.
h no event in patients with PAD.
Women
5% CI Pre-event 95% CI Postevent 95% CI
0.162 0.101 to 0.424
2 to 0.308 0.355 0.071 to 0.782 0.137 0.315–0.590
2 to 0.199 0.177 0.033–0.388 0.151 0.075 to 0.377
4 to 0.606 0.018 0.702 to 0.667 0.040 0.746 to 0.666
4 to 0.440 0.203 0.149 to 0.556 0.208 0.195 to 0.611
04–0.310 0.186 0.059–0.314 0.173 0.038–0.307
38–0.204 0.117 0.010–0.334 0.105 0.007 to 0.217
-5D score for patients without an event at 3-mo postintervention and
This difference can be divided by 12 to get the QALY loss for being 1wit
9
0.10
0.26
0.10
0.01
d EQ
ively.wit
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0.19
0.69
0.14
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181V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 7 5 – 1 8 2not assessed. Therefore, we cannot correct for any changes in co-
morbid conditions.
One of the major reasons for embarking on this study was that
single trials do not accumulate enough events to give reliable es-
timates. This is most clearly shown in the very low number of
change scores formost events fromeachseparate trial. The results of
our current study emphasize the need for pooling of studies: several
clinically relevant estimates from events with low frequency (CVA
and MI) and estimates for older patients were not significant,
while much smaller estimates from reintervention (the largest
group) were highly significant.
A major point of discussion is the extrapolation of the pre-
event estimates. Patients without an event show quick improve-
ment after the vascular intervention. It is therefore not likely that
patients with a late secondary event do not improve at all in the
period after the intervention. Extrapolation of the estimated
health status loss of an event to the intervention day is likely an
overestimation of the actual impact. Neglecting the loss of health
status before the event, however, is a major underestimation of
the impact. We recommend that future studies measure health
status more often, for example, monthly and preferably immedi-
ately after an event. This way the course of health status and the
impact of secondary events on health status can be assessed with
more detail and confidence.
Estimated impact of secondary events in men with CHD
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Fig. 1 – Estimated impact of secondary events in men with
coronary heart disease.
Estimated impact of secondary events in women with CHD
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Fig. 2 – Estimated impact of secondary events in women
with coronary heart disease.Comparison with published estimates
Wecould not find estimates of the impact of cardiovascular events
on health status, except for CVAs. Current estimates of the impact
of CVA on health status are based on reviews of published litera-
ture [13,15,16]. The estimates of the impact of a secondary stroke
that we found are much lower than those found by these studies.
Thismay be attributable to a number of causes. Amajor drawback
of these studies is that they do not directly estimate the impact of
events, but only use published articles and combine results from
other studies, all using different methodologies. Ours is the first
study that uses individual patient data instead of data from other
articles. Another important difference is the difference in patient
groups. We used data from patients with CHD or PAD who under-
went revascularization. Post et al. [13] reported expected utilities
for new events from patients at risk of stroke and from stroke
survivors. Interestingly, stroke survivors assignedhigher expected
utilities than did patients at risk. This is in line with our findings.
Furthermore, the articles by Tengs and Post [13–16] try to assess
the expected utility of hypothetical events, while we assessed the
impact of actual secondary events. A further critique of the first
study by Tengs et al. [16] is that they pooled estimates from pa-
tients, researchers, and expert panels. The utility estimates from
their second study [15] aremuch higher—and closer to ours—than
Impact of secondary events in men with PAD
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Fig. 3 – Estimated impact of secondary events in men with
peripheral arterial disease.
Estimated impact of secondary events in women with PAD
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Fig. 4 – Estimated impact of secondary events in women
with peripheral arterial disease.
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182 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 7 5 – 1 8 2those from their first study. Another study by Tengs and cowork-
ers [14] gives, among others, estimates for cardiovascular events
other than stroke. This review, however, only reports a large
amount of estimates taken from the literature, without further
analysis.
Conclusion
Newcardiovascular events after revascularization in patientswith
cardiovascular disease are associated with loss of health status
both before and after the event. Patients with any type of event
had decreased health status both before and after the event when
compared with patients without events. The acute impact of sec-
ondary events was smaller than expected, except for amputation.
The resulting estimates of the impact of secondary cardiovas-
cular events will be useful in reducing the uncertainty in long-
term economic modeling. Future cost-effectiveness studies
should measure health status more often and more rigorously.
Health status should be measured as soon as possible after a car-
diovascular event to capture the full impact.
Source of financial support: This studywas supported by Neth-
erlands Heart Foundation grant 2002B45.
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